Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

ENZYCHEM LIFESCIENCES CORPORATION

엔지켐생명과학183490KOSDAQSector: Pharma & Biotech
₩9900.00%Market cap ₩83.8BAs of Sep 1, 2026 close · updated once daily
Market cap
₩83.8B
#807 in KOSDAQ
Loss
PER not computable
0.61x
Sector median 1.61x
0.0%
Sector median 0.0%
Trading halted — grade display suspended

This stock is under a trading halt per KRX disclosure. Grade display resumes once trading resumes.

See withholding criteria →View source filing (DART) ↗

This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1-year closing price

Loading closing price history…
 
Low ₩989High ₩1,699
Latest close
Price change by period
1W
0.00%
1M
0.00%
3M
0.00%
1Y
0.10%

As of the Sep 1, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

65.5/100
How much debt does it carry relative to equity?
7.1%
Sector median 51.6%
Sector lowhighTop 7.5% in sector
Can it cover what's due within a year?
1406.4%
Sector median 191.7%
Sector lowhighTop 10.3% in sector
How much of revenue becomes profit?
-21.2%
Sector median -2.4%
Sector lowhighBottom 39.1% in sector
How much did it earn on its own capital?
-13.2%
Sector median -4.5%
Sector lowhighBottom 40.7% in sector

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

48.7/100
How much did revenue grow in a year?
-12.4%
Sector median 6.4%
Sector lowhighBottom 16.6% in sector
Has it grown steadily over three years?
36.5%
Sector median 4.9%
Sector lowhighTop 8.5% in sector
Did core profits grow in a year?
-8.7%
Sector median 3.6%
Sector lowhighBottom 37.6% in sector
Are core profits higher than three years ago?
2.2%
Sector median 3.5%
Sector lowhighBottom 49.2% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

48.6/100
Is the price expensive relative to earnings?
Loss-making (P/E not computable)
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighBottom 14% in sector
Is the price expensive relative to book value?
0.61x
Sector median 1.61x
Sector lowhighTop 16.8% in sector

Valuation uses the Sep 1, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Dividends & treasury shares

Treasury shares (FY2025)
10,196,500 shares (11.9% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 6 met · 3 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Not met
-₩18.1B
Positive operating cash flow
Whether cash flow from operations is above zero.
Not met
-₩11B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Met
-10.5% → -10.0%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
-₩11B vs -₩18.1B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Met
11.1% → 6.6%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Met
1303.1% → 1406.4%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Met
85,065,562 → 85,065,562
Operating margin up
Whether operating income over revenue rose from the prior year.
Not met
-17.1% → -21.2%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Met
0.366x → 0.373x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026B→F

Methodology version change (v2.0 applied)

Jul 15, 2026BVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Management-dispute lawsuit filing

A filing under the KRX form “소송등의제기ㆍ신청(경영권분쟁소송)” (filing/petition of lawsuit — management dispute) was received (received 2026-07-22). View filing ↗

Financial fact combinations

Operating losses for 3 consecutive fiscal years

Recorded operating losses in three consecutive fiscal years, FY2023–FY2025 (per annual reports).

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Management-dispute lawsuit filedJul 22, 2026Source ↗
Management-dispute lawsuit filedJul 8, 2026Source ↗
Management-dispute lawsuit filedJul 8, 2026Source ↗
Management-dispute lawsuit filedJul 8, 2026Source ↗

View in the filings calendar →